From: Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children
Study | Model | Time Horizon | Perspective | Population | Intervention | Comparator | Effects |
---|---|---|---|---|---|---|---|
Nuijten [45] | Decision tree | Lifetime | UK National Health Service and society | Pre-term infants and children with BPD | Palivizumab | No prophylaxis | Number of RSV hospitalizations avoided |
Omnes [46] | Decision tree | 7 years (6 years-adults) | French Social Security | Children and adults | Specific immunotherapy (injectable and sublingual) | Current symptomatic treatment | Proportions of individuals with rhinitis or allergic asthma |
Resch [47] | Decision tree | Lifetime | Austrian third party payer and society | Infants born premature or with BPD, and children with congenital heart disease | Palivizumab | No prophylaxis | Life years gained and QALY gained |
ElHassan [48] | Markov (with and without increased asthma risk due to RSV infection) | 1 year (no-risk); 8-10 years (with risk) | US society | Premature infants | Palivizumab | No prophylaxis | QALY gained |
BrĂ¼ggenjĂ¼rgen [49] | Markov model | 15 years | German third party payer and society | Children (6 to 12 years), adolescents (13 to 18 years), and adults (19 to 65 years) | Specific immunotherapy (subcutaneous) and symptom treatment | Symptom treatment | QALY gained |